Compare BLDR & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLDR | RVMD |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 15.2B |
| IPO Year | 2005 | 2020 |
| Metric | BLDR | RVMD |
|---|---|---|
| Price | $103.11 | $79.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 17 |
| Target Price | ★ $141.37 | $77.47 |
| AVG Volume (30 Days) | 1.6M | ★ 2.4M |
| Earning Date | 02-19-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.26 | N/A |
| Revenue | ★ $15,653,056,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $714.50 |
| P/E Ratio | $19.57 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $94.35 | $29.17 |
| 52 Week High | $175.12 | $81.97 |
| Indicator | BLDR | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.71 | 63.61 |
| Support Level | $102.18 | $78.97 |
| Resistance Level | $104.27 | $81.97 |
| Average True Range (ATR) | 2.67 | 2.21 |
| MACD | -0.04 | -0.53 |
| Stochastic Oscillator | 11.21 | 77.26 |
Builders FirstSource Inc is a manufacturer and supplier of building materials. The company offers structural and related building products such as factory-built roof and floor trusses, wall panels and stairs, vinyl windows, custom millwork and trim, and engineered wood. The products can be designed for each home individually and are installed by Builders FirstSource. The company's construction-related services include professional installation, turn-key framing, and shell construction. Builders FirstSource's customers range from large production builders to small custom homebuilders.
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio and SOS1 and 4EBP1/mTORC1 programs.